ARNI.US Arno Therapeutics

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Jun 11, 2026
0.0001 0.0002
Market cap
USD 4.93K
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2016.

Is ARNI.US undervalued?

Graham number

The Graham number of Arno Therapeutics cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Arno Therapeutics fundamental analysis

No fundamental analysis for Arno Therapeutics yet.

Arno Therapeutics stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Arno Therapeutics

Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of …

Full company profile